In the 8-week clinical studies, up to 46% of patients achieved clear or almost clear skin compared to 18% on cream with no active ingredient.
In the 12-week clinical studies, up to 40% of adult patients achieved clear or almost clear skin compared to 6% on cream with no active ingredient.
Use our online tool to locate a dermatologist in your area who can help determine if VTAMA cream is right for you.
Search Now
Prefer the convenience of telehealth?
Connect virtually with a board-certified dermatologist.
*Eligibility required. This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program.
Indications: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for:
Adverse Events: In plaque psoriasis, the most common adverse reactions (incidence ≥1%) were: red raised bumps around the hair pores (folliculitis), pain or swelling in the nose and throat (nasopharyngitis), skin rash or irritation, including itching and redness, peeling, burning, or stinging (contact dermatitis), headache, itching (pruritus), and flu (influenza).
Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, red raised bumps around the hair pores (folliculitis), lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and stomach-area (abdominal) pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please read the Prescribing and Patient Information for VTAMA cream and discuss it with your doctor.
Back to top
